Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSMB9 | P28065 | 1/20 | 0.47 |
| ▸ | TACR1 | P25103 | 4/20 | 0.40 |
| ▸ | XIAP | P98170 | 5/20 | 0.39 |
| ▸ | CFD | P00746 | 8/20 | 0.39 |
| ▸ | DPP4 | P27487 | 1/20 | 0.37 |
| ▸ | BIRC3 | Q13489 | 1/20 | 0.37 |
| ▸ | BIRC2 | Q13490 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30874916 | 0.90 | PSMB9 (0.45) | PSMB9TACR1XIAPCFDDPP4 | |
| SCHEMBL29230642 | 0.89 | PSMB9 (0.45) | PSMB9TACR1XIAPCFDDPP4 | |
| SCHEMBL29230716 | 0.89 | PSMB9 (0.48) | PSMB9TACR1XIAPCFD | |
| SCHEMBL24666170 | 0.89 | PSMB9 (0.45) | PSMB9TACR1XIAPCFDDPP4 | |
| SCHEMBL26817652 | 0.89 | PSMB9 (0.48) | PSMB9TACR1XIAPCFD | |
| SCHEMBL29231195 | 0.85 | XIAP (0.43) | PSMB9TACR1XIAPCFDBIRC3 | |
| SCHEMBL29231182 | 0.85 | CFD (0.44) | TACR1XIAPCFD | |
| SCHEMBL24665928 | 0.85 | XIAP (0.43) | PSMB9TACR1XIAPCFDBIRC3 | |
| SCHEMBL29231187 | 0.85 | CFD (0.44) | TACR1XIAPCFD | |
| SCHEMBL29231188 | 0.85 | CFD (0.44) | TACR1XIAPCFD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11814367-B2 | Inhibitors of glycogen synthase 1 (GYS1) and methods of use thereof | MAZE THERAPEUTICS, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-11814367-B2 | Inhibitors of glycogen synthase 1 (GYS1) and methods of use thereof | MAZE THERAPEUTICS, INC. (US) | 2023-11-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11814367-B2 | Inhibitors of glycogen synthase 1 (GYS1) and methods of use thereof | GYS2, GYS1, PYGL | PSMB9 4031/4885TACR1 4794/4885XIAP 1299/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.